Anti-Cancer Drug Des 10: 299–309,1995. Stevenson JP, Gallagher M, Sun W, Algazy K, Vaughn DJ, Haller DG, Hiller K, Halloran L, O'Dwyer J Phase I/pharmacokinetic trial of the endothelial toxin combretastatin A4P (CA4P) administered as an IV bolus on a daily 5 schedule every 21 days. Proc Am Assoc Cancer Res 41: 54, 2000. Thompson M. „Combrestatin - Molecule of the month”. Bristol University Chemistry Dept Home Page. Bristol University. Publikacja 6 IX 2005 kopia z 20 IX 2006.
Kategoria:Polifenole Kategoria:ATC-L01